ConductScience.org, home

Paper33100710

Effectiveness and Cost-Effectiveness of Prophylactic Voriconazole and Fluconazole Regarding Prevention of Post-hematopoietic Stem Cell Transplantation Invasive Fungal Infection and Its Related Death: A Single Center Experience.

El-Ghammaz AMS and 7 others. Indian J Hematol Blood Transfus, 2020. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Effectiveness and Cost-Effectiveness of Prophylactic Voriconazole and Fluconazole Regarding Prevention of Post-hematopoietic Stem Cell Transplantation Invasive Fungal Infection and Its Related Death: A Single Center Experience. Papers, record 33100710. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33100710

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effectiveness and Cost-Effectiveness of Prophylactic Voriconazole and Fluconazole Regarding Prevention of Post-hematopoietic Stem Cell Transplantation Invasive Fungal Infection and Its Related Death: A Single Center Experience.
PubMed
Journal
Indian J Hematol Blood Transfus
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.17
iCite
Revised in PubMed
2022-04-17
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1El-Ghammaz AMSAmro Mohamed Sedkyhttps://orcid.org/0000-0002-1567-7511
2El-Zimaity MMahahttps://orcid.org/0000-0003-2221-968X
3Elafifi AMAmal Mostafa
4Abdelwahed EEssam
5Moussa MMMohamed Mahmoud
6Aboelmagd YAYasmin Ahmed
7Kotob MGMohamed Gamal
8Fares HMHebatullah Magdy

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125887385Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.BMC Infect Dis2015https://conductscience.org/library/papers/25887385PubMed
21542320A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.N Engl J Med1992https://conductscience.org/library/papers/1542320PubMed
320826719Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.Blood2010https://conductscience.org/library/papers/20826719PubMed
417287717Trends in the epidemiology of invasive fungal infections.Nihon Ishinkin Gakkai Zasshi2007https://conductscience.org/library/papers/17287717PubMed
57769290Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.J Infect Dis1995https://conductscience.org/library/papers/7769290PubMed
617251530Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.N Engl J Med2007https://conductscience.org/library/papers/17251530PubMed
712005089Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.Pediatr Infect Dis J2002https://conductscience.org/library/papers/12005089PubMed
815994282Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.Blood2005https://conductscience.org/library/papers/15994282PubMed
921042306Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success.Bone Marrow Transplant2011https://conductscience.org/library/papers/21042306PubMed
1024372659The role of primary antifungal prophylaxis in patients with haematological malignancies.Clin Microbiol Infect2014https://conductscience.org/library/papers/24372659PubMed
1121082966Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.Expert Rev Hematol2009https://conductscience.org/library/papers/21082966PubMed
1216944217Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants.Support Care Cancer2007https://conductscience.org/library/papers/16944217PubMed
1321880032Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.Br J Haematol2011https://conductscience.org/library/papers/21880032PubMed
1424026863Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species.Eur J Clin Microbiol Infect Dis2014https://conductscience.org/library/papers/24026863PubMed
1520035021Safety of triazole antifungal drugs in patients with cancer.J Antimicrob Chemother2010https://conductscience.org/library/papers/20035021PubMed
1623943184Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.Am J Health Syst Pharm2013https://conductscience.org/library/papers/23943184PubMed
1721657801Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence.Pharmacoeconomics2011https://conductscience.org/library/papers/21657801PubMed
1818781877Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation.Clin Infect Dis2008https://conductscience.org/library/papers/18781877PubMed
1927663309Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study.J Hematol Oncol2016https://conductscience.org/library/papers/27663309PubMed
2012689933Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.Blood2003https://conductscience.org/library/papers/12689933PubMed

See all 27 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42842202Antifungal prophylaxis in patients with haematological malignancies receiving chemotherapy or haematopoietic stem cell transplantation: a systematic review and network meta-analysis.Infection2026https://conductscience.org/library/papers/42842202PubMed
37887786Septic Obturation of a Knee Endoprosthesis Caused by Aspergillus clavatus.Pathogens2023https://conductscience.org/library/papers/37887786PubMed
33538201Current and promising pharmacotherapeutic options for candidiasis.Expert Opin Pharmacother2021https://conductscience.org/library/papers/33538201PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33100710

GET https://conductscience.org/api/papers/v1/33100710/references?page=2